TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Cyclophosphamide, Doxorubicin, Vincristine w/ Irinotecan and Temozolomide in Ewings Sarcoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed diagnosis of metastatic Ewing's sarcoma.~* Patients must have measurable disease defined as lesions that can be measured by medical imaging techniques such as CT or MRI. Ascites, pleural fluid, bone marrow disease, lesions seen on scan will not be considered measurable.~* Patients must have metastatic disease.~* Age 13 years or older~* Life expectancy of at least 3 months.~* ECOG performance status of \<= 3.~* Normal hepatic function (Direct bilirubin \<1.5mg/dl, SGOT or SGPT \<3x upper limit of normal).~* Left Ventricular Ejection fraction of at least 50%.~* Adequate renal function: Creatinine clearance \>= 50 ml/min or Serum creatinine \< 1.5 x ULN for age.~* Adequate bone marrow reserve (defined as an absolute peripheral granulocyte count of \>=1500/mm3, platelet count of \>=75,000/mm3); unless bone marrow infiltrated with metastatic Ewing's sarcoma; ANC \>= 500 and Platelet \>= 50,000 mm3.~* Ability to understand and willing to sign a written informed consent document.~* Patients of childbearing potential must agree to use an effective method of contraception.~Exclusion Criteria:~* No prior chemotherapy for Ewing's sarcoma; No prior doxorubicin, temozolomide or irinotecan.~* Known hypersensitivity to any of the components of the protocol drugs.~* Clinically significant unrelated systemic illness (such as serious infections requiring active systemic intravenous antibiotic therapy; cardiovascular disease \[congestive heart failure, recent myocardial infarction, unstable angina, inadequately controlled hypertension\].~* No prior history of chronic diarrhea, bowel obstruction, Crohn's disease or ulcerative colitis.~* Pregnant or nursing woman are not included in the study.~* HIV-positive patients will be excluded from the study due to risk of infection or other serious side effects.~* Other medical, psychiatric or social condition incompatible with study treatment.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination Therapy (Type: EXPERIMENTAL): Regimen A alternating with Regimen B every 21 days~Regimen A:~* Cytoxan 1200mg/m2~* Doxorubicin, starting dose 75 mg/m2 to a maximum of 450mg/m2~* Vincristine, starting dose 2 mg/m2 to a maximum of 2 mg~* Pegfilgrastim, 6 mg subcutaneous within 24 to 48 hours after each cycle~Regimen B:~* Irinotecan 50 mg/m2/day x 5 days~* Temozolomide 100 mg/m2/day x 5 days followed by 2 weeks treatment-free

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Tendon Transfer, Botox Injections and Ongoing Treatment in Hemiplegic Cerebral Palsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of UECP~* aged four to 17 years~* candidate for standard surgical management (tendon transfer)~Exclusion Criteria:~* subject could benefit from procedures in addition to standard surgical management and releases, and these procedures could be performed at the same anesthetic (for example, elbow flexor release)~* previous Botulinum toxin injection session in the affected UE in \< 1 year~* previous ipsilateral UE surgery~* primary language other than English or Spanish~* subject and/or parent unwilling to attend eight therapy sessions and perform home exercise protocol

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Therapy Group (Type: ACTIVE_COMPARATOR): Therapy only
- Surgery Group (Type: ACTIVE_COMPARATOR): surgical intervention
- Botox Injections (Type: ACTIVE_COMPARATOR): botulinum toxin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Different Doses of Tomato Lycopene on Blood Pressure in Pre-hypertensive Otherwise Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 35-60,~* No antihypertensive treatment in the past or present,~* 135\< SBP\< 145 or 85\<DBP\<95,~* Informed consent signed,~Exclusion Criteria:~* Unwilling to participate in the study,~* Treated essential,~* secondary or complicated hypertension,~* SBP lower than 135 or higher than 145 mmHg,~* DBP lower than 85 or higher than 95 mmHg,~* Use of other medications (statins, NSAI ect..),~* Known allergy to tomato, carotenoids, or vitamin E,~* Diabetes Mellitus,~* Obesity BMI\>32,~* Significant dyslipidemia,~* Patients with ischemic pain, S/P MI, PTCA or CABG, LVH or CHF,~* Smoker,~* Valvular heart disease,~* PVD,~* Cerebrovascular disease, s/p CVA, TIA,~* Any kind of kidney disease (creatinine\>1.6),~* Chronic liver disease(elevated AST and ALT at least by 2 times of the normal range),~* Alcohol abuse,~* History of GI disease or surgery,~* History of malignancy in the past 5 years,~* History of autoimmune disease,~* Participation in other researches protocol

- Gender: ALL
- Minimum Age: 35 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: PLACEBO_COMPARATOR): None
- 2 (Type: ACTIVE_COMPARATOR): Lyc-o-Mato 5mg
- 3 (Type: ACTIVE_COMPARATOR): Lyc-o-Mato 15mg
- 4 (Type: ACTIVE_COMPARATOR): Lyc-o-Mato 30mg
- 5 (Type: ACTIVE_COMPARATOR): Lycopene capsules (non Lyc-o-mato) 15 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metronomic Therapy in Patients With Metastatic Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
* Metastatic melanoma with measurable disease~* Patients must be at least 4 weeks from their last immunotherapy, radiation, surgery or chemotherapy (6 weeks for nitrosoureas) and recovered from all ill~* Karnofsky Performance Status ≥60%~* Life expectancy ≥ twelve weeks~* Adequate end organ function~* Women should not be lactating and, if of childbearing age, have a negative pregnancy test within two weeks of entry to the study.~* Appropriate Contraception in both sexes~* The patient must be competent and signed informed consent.~EXCLUSION CRITERIA~* Concomitant second malignancy except for non-melanoma skin cancer, and non-invasive cancer such as cervical CIS, superficial bladder cancer without local recurrence, breast CIS.~* In patients with a prior history of invasive malignancy, less than five years in complete remission.~* Have evidence of significant co-morbid illness such as uncontrolled diabetes - Uncontrolled brain metastasis: Patients with brain metastasis most have been treated with brain radiation therapy or surgery and remain clinically stable for a minimum of 4 weeks.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combined Low Dose Treatment (Type: EXPERIMENTAL): A cycle of therapy is 3 weeks of continuous dosing with a 1 week rest.~Schema of treatment is:~1 mg/m2 vinblastine three times a week iv 60 mg/m2 cyclophosphamide by mouth 15 mg/m2 dacarbazine three times a week iv

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Phosphate Binders on Markers of Vascular Health in Chronic Kidney Disease Stages 3 and 4

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females ≥ 18 years of age at start of screening~* CKD stage 3 or 4 defined by an eGFR 15 - 60 mL/min/1.73m2~* Not expected to start dialysis for 8 months~* Serum intact PTH \< 500 pg/mL during screening period~* On a stable ACE inhibitor/ARB regimen for 30 days prior to screening~Exclusion Criteria:~* History of any of the following diseases: congestive heart failure, MI within the last 6 months, cerebrovascular accident, significant valvular disease, malignancy~* Currently receiving erythropoiesis stimulating agent or IV iron therapy~* History of inflammatory/autoimmune disease~* History of polycystic kidney disease~* HIV positive or AIDS~* Pregnant or breastfeeding~* Receiving activated Vitamin D analogs, nutritional vitamin D agents \> 2,000 IU/day, or calcimimetics with in the last 3 months~* Significant GI disorder~* Proteinuria \>3.5 g/24 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sevelamer carbonate (Type: EXPERIMENTAL): 1,600 mg (2 x 800 mg) three times daily with meals for a total of 12 weeks
- Calcium acetate (Type: ACTIVE_COMPARATOR): 1,334 mg (2 x 667 mg) three times daily with meals for a total of 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Systemic Steroids Plus Antibiotics in Sleep Apnea Syndrome in Children

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Polysomnogram results showing mild obstructive sleep apnea.~Exclusion Criteria:~* Significant medical problems~* Chronic medication intake (except bronchodilators and inhaled steroids)~* Allergy to penicillin or its derivatives.

- Gender: ALL
- Minimum Age: 18 Months
- Maximum Age: 12 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assess Safety, Tolerability and Pharmacokinetic (PK) of AZD1704 in Healthy Japanese Male and Non-Fertile Female Volunteers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy Japanese males and non-fertile females, defined as first generation Japanese (both parents and grandparents are of Japanese origin, the subject is born in Japan and has not been living outside of Japan for more than 5 years) aged 20-45 years .~* Clinical normal physical findings~* BMI 19 - 27, weight 50 - 95 kg~Exclusion Criteria:~* History of somatic disease/condition or ongoing psychiatric disease/condition that may interfere with the objectives of the study.~* History of psychotic disorder among first-degree relatives.~* History of use of antipsychotic, antidepressant or anxiolytic drugs, prescribed as well as non-prescribed use.~* Smoking more than 7 cigarettes per week or consumption of more than 3 portion of snuff or equivalent per day within 30 days before administration of study drug.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Four different oral dose levels of a suspension containing AZD1704
- 2 (Type: PLACEBO_COMPARATOR): oral suspension

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of a Virtual Care Clinic in the Management of Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 Diabetes~* Access and the ability to use the internet on a computer or mobile device~* Access to a family physician and lab for blood tests~Exclusion Criteria:~* Patients that are pregnant or attempting to conceive~* Liver disease (AST or ALT levels \>2.5 times the reference level)~* Renal insufficient with a serum creatine level \>200 umol/L~* Patients who see an endocrinologist or diabetes specialist within their community

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Interventional Group (Type: EXPERIMENTAL): The recruited participants will be provided access to Virtual Care suite via internet and telephone communication.
- Standard of Care (Type: ACTIVE_COMPARATOR): The recruited participants will receive the standard of diabetes care as offered by the services in their community.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Assessing Suicide Risk in Adolescents With Developmental Delays

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
* INCLUSION CRITERIA:~Client must be enrolled in individual counseling at the Surrey Center at time of participation and must have attended at least 3 therapy appointments.~Clients must have an IQ score betwen 55 and 75 (a range considered to mild developmental delay). A client with mild DD will have the ability to communicate verbally and provide writtent assent. In order to receive services at Surrey Place Centre, clients must have a designation of developmental delay with and IQ score or range. If they do not have an IQ Score or DD designation, they undergo assessment at intake. Therefore, each client will have an IQ score recorded prior to study recruitment.~Age 12 years or older~English speaking~A legal guardian must provide informed consent and client must sign an assent document. Verbal assent is not acceptable for participation.~EXCLUSION CRITERIA:~Legal guradian is non-English speaking and no translation support is available to assist with the consent process.~No IQ score on record.

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tolerability of Enecadin (INN) in Acute Ischemic Stroke Trial - TEST

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with acute ischemic stroke (scoring 3-20 on the National Institutes of Health Stroke Scale \[NIHSS\]) with level of consciousness score: 0 or 1 (conscious patients) are eligible to be treated within 9 hours of onset of stroke symptoms.~* For female patients: post-menopausal or surgically sterile (post-menopausal: age ≥55 years and last menses ≥3 years ago).~Exclusion Criteria:~* Participation in any investigational study in the previous 30 days.~* Patients unable to understand trial related information.~* History or evidence of severe heart diseases further specified in the protocol.~* History or evidence of additional diseases or results of baseline visit as specified in the protocol.~* Use of concomitant and prior medications as defined in the protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Enecadin
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Stent Versus Conservative Treatment in Patients With Deep Venous Obstruction

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>18 years~* Meet criteria for PTS or~* Patients with May Thurner syndrome on additional imaging~* Life expectancy of more than one year~* Deep venous thrombosis \> 1 year~* Signed informed consent~Exclusion Criteria:~* Previous intervention of central veins (inferior vena cava, iliac veins, common femoral vein) on the affected limb~* Known pregnancy~* Inability to answer Dutch QoL questionnaires or limited communication in Dutch (written and spoken)~* Contra-indication for prolonged anticoagulant treatment~* Recent, \<1 year, deep venous thrombosis or pulmonary Embolism~* Known contrast allergy~* Known dialysis or renal insufficiency needing additional preparation for injection of contrast

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- deep venous stent (Type: ACTIVE_COMPARATOR): Patients will receive deep venous stenting in the iliaco(femoral) region
- conservative managment (Type: NO_INTERVENTION): Conservative management of complaints

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Males or postmenopausal or surgically sterilized females, who have type 2 diabetes mellitus~* Medically stable on the basis of physical examination, medical history, laboratory safety test results, vital signs and ECG performed at screening~* Body Mass Index (BMI) between 22 and 39.9 kg/m2, inclusive~* On a generally stable antihyperglycemic agent regimen (i.e. with no change in medication, or only 1 dose step change in dose) for at least 2 months prior to Screening visit, including volunteers who are: (a) Not currently on antihyperglycemic therapy and have an HbA1c \>=7.0 % and \<=10%, or (b) On a single oral antihyperglycemic agent \[metformin, a sunfonylurea, a meglitinide (e.g., repaglininide or nateglinide), a DPP-IV inhibitor (sitagliptin or vildagliptin), or an alpha-glucosidase inhibitor (e.g., acarbose)\] and have an HbA1c \>=6.5% and \<=9.5%, or (c) On low-dose dual oral agent therapy (i.e., \<50% maximum labeled doses of both agents) and have an HbA1c \>=6.5% and \<=9.5%~* On Day -2 (two days prior to study drug administration), FPG concentrations between 120 mg/dL and 260 mg/dL, inclusive~Exclusion Criteria:~* Taking non-oral antihyperglycemic agent (e.g., insulin, exenatide or other GLP-1 analogues), or taking a thiazolidinedione (i.e., a PPARg agonist) within 3 months of the Screening visit~* History of a recent severe hypoglycemic episode, recurrent hypoglycemic episodes (i.e., within the past year), or a history of hypoglycemic unawareness~* History of clinically significant diabetic complications, including retinopathy, nephropathy, neuropathy or gastroparesis~* Positive test for alcohol and/or drugs of abuse~* Psychological and/or emotional problems, which would render the informed consent invalid, or limit the ability of the volunteer to comply with the study requirements~* Any condition that, in the opinion of the investigator, would compromise the well being of the volunteer or the study or prevent the volunteer from meeting or performing study requirements

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues